Sofosbuvir for previously untreated chronic hepatitis C infection.

@article{Lawitz2013SofosbuvirFP,
  title={Sofosbuvir for previously untreated chronic hepatitis C infection.},
  author={Eric Lawitz and Alessandra Mangia and David L. Wyles and Norman Gitlin and Tarek I. Hassanein and Stuart C. Gordon and Michael H. Schultz and Mitchell N Davis and Zeid K Kayali and K Rajender Reddy and Ira M Jacobson and Kris V. Kowdley and Lisa M. Nyberg and Gopinath M. Subramanian and Robert H. Hyland and Sarah Arterburn and Deyuan Jiang and John McNally and Diana M. Brainard and William T. Symonds and John McHutchison and Aasim M. Sheikh and Zobair M Younossi and Edward J. Gane},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 20},
  pages={
          1878-87
        }
}
BACKGROUND In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection. METHODS We conducted two phase 3 studies in previously untreated patients with HCV infection. In a single-group, open-label study, we administered a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with HCV genotype 1, 4, 5, or 6 (of whom 98% had genotype 1 or 4). In… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 872 CITATIONS, ESTIMATED 38% COVERAGE

Chapter 3 Advances in HCV Therapy

VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2015
VIEW 12 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Sofosbuvir, a Significant Paradigm Change in HCV Treatment

  • Journal of clinical and translational hepatology
  • 2015
VIEW 16 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Sofosbuvir: First Global Approval

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 79 Highly Influenced Citations

  • Averaged 72 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2013

New pharmacotherapy for hepatitis C.

  • Clinical pharmacology and therapeutics
  • 2012

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Sprint Investigators
  • 2011
VIEW 2 EXCERPTS

Hepatitis C virus infection in USA: an estimate of true prevalence.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2011

Similar Papers

Loading similar papers…